Pfizer's sigvotatug vedotin fails Phase 3 lung cancer trial, the third Seagen-acquired ADC to disappoint in roughly a year.
Albert Bourla, Pfizer CEO (AP Photo/Markus Schreiber)
June 23, 2026 10:44 AM EDTUpdated 12:29 PM
R&DPharma
Pfizer's $43B Seagen bet sours further as ADC fails in late-stage lung cancer trial
Elizabeth Cairns
Pfizer drug acquired in Seagen deal disappoints in lung cancer study
Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients - Pfizer (NYSE:
Closely watched Pfizer lung cancer drug falls short in clinical trial
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Amid safety concerns, ADC Therapeutics plots 17% staff cuts to push resources behind Zynlonta
Europe's CHMP reverses endorsement of Amgen's Tavneos as FDA hearing looms
